25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Daihan Pharmaceutical Co.Ltd
Buy, Hold or Sell?

Let's analyze Daihan together

I guess you are interested in Daihan Pharmaceutical Co.Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Daihan Pharmaceutical Co.Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Daihan Pharmaceutical Co.Ltd

I send you an email if I find something interesting about Daihan Pharmaceutical Co.Ltd.

1. Quick Overview

1.1. Quick analysis of Daihan (30 sec.)










1.2. What can you expect buying and holding a share of Daihan? (30 sec.)

How much money do you get?

How much money do you get?
₩0.00
When do you have the money?
1 year
How often do you get paid?
79.3%

What is your share worth?

Current worth
₩44,191.97
Expected worth in 1 year
₩48,205.18
How sure are you?
100.0%

+ What do you gain per year?

Total Gains per Share
₩4,013.21
Return On Investment
14.9%

For what price can you sell your share?

Current Price per Share
₩26,950.00
Expected price per share
₩23,750 - ₩27,550
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Daihan (5 min.)




Live pricePrice per Share (EOD)
₩26,950.00

2.2. Growth of Daihan (5 min.)




Is Daihan growing?

Current yearPrevious yearGrowGrow %
How rich?$181.8m$159.6m$15.9m9.1%

How much money is Daihan making?

Current yearPrevious yearGrowGrow %
Making money$5.2m$4.6m$615.1k11.7%
Net Profit Margin15.2%13.8%--

How much money comes from the company's main activities?

2.3. Financial Health of Daihan (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Daihan?

Welcome investor! Daihan's management wants to use your money to grow the business. In return you get a share of Daihan.

First you should know what it really means to hold a share of Daihan. And how you can make/lose money.

Speculation

The Price per Share of Daihan is ₩26,950. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Daihan.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Daihan, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ₩44,191.97. Based on the TTM, the Book Value Change Per Share is ₩1,003.30 per quarter. Based on the YOY, the Book Value Change Per Share is ₩1,137.53 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ₩0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Daihan.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps0.950.0%0.890.0%0.780.0%0.730.0%0.750.0%
Usd Book Value Change Per Share0.950.0%0.700.0%0.800.0%0.660.0%1.070.0%
Usd Dividend Per Share0.000.0%0.000.0%0.230.0%0.180.0%0.170.0%
Usd Total Gains Per Share0.950.0%0.700.0%1.030.0%0.830.0%1.240.0%
Usd Price Per Share19.57-19.54-19.43-20.77-22.98-
Price to Earnings Ratio5.12-5.56-7.04-4.38-5.77-
Price-to-Total Gains Ratio20.50-31.64-20.63-35.26-33.80-
Price to Book Ratio0.63-0.65-0.72-0.88-1.19-
Price-to-Total Gains Ratio20.50-31.64-20.63-35.26-33.80-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share18.865
Number of shares53
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.18
Usd Book Value Change Per Share0.700.66
Usd Total Gains Per Share0.700.83
Gains per Quarter (53 shares)37.2244.23
Gains per Year (53 shares)148.89176.93
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1014913937139167
2029828875279344
30447437112418521
40596586150558698
50744735187697875
608938842258371052
70104210332629761229
801191118230011161406
901340133133712551583
1001489148037513951760

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%12.00.00.0100.0%19.01.00.095.0%28.01.00.096.6%28.01.00.096.6%
Book Value Change Per Share4.00.00.0100.0%12.00.00.0100.0%19.01.00.095.0%28.01.00.096.6%28.01.00.096.6%
Dividend per Share0.00.04.00.0%6.00.06.050.0%14.00.06.070.0%23.00.06.079.3%23.00.06.079.3%
Total Gains per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%29.00.00.0100.0%29.00.00.0100.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Daihan Pharmaceutical Co.Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--1363.6441003.303+36%1137.534+20%939.716+45%1523.861-11%
Book Value Per Share--44191.97242676.931+4%38415.242+15%34847.118+27%30653.011+44%
Current Ratio--3.2353.591-10%3.880-17%3.340-3%2.900+12%
Debt To Asset Ratio--0.1500.156-4%0.183-18%0.238-37%0.284-47%
Debt To Equity Ratio--0.1760.184-4%0.225-22%0.321-45%0.418-58%
Dividend Per Share----0%335.180-100%252.521-100%241.460-100%
Enterprise Value--118601964000.000117901282855.000+1%214756737670.000-45%179074683463.500-34%172415963844.483-31%
Eps--1363.6441277.041+7%1117.507+22%1042.517+31%1073.382+27%
Ev To Ebitda Ratio--infinfnan%infnan%infnan%infnan%
Ev To Sales Ratio--0.6070.595+2%1.118-46%1.004-40%1.009-40%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Market Cap158466000000.000-4%164346000000.000164125500000.000+0%164935500000.0000%177022200000.000-7%196246344827.586-16%
Net Profit Margin--0.1640.152+8%0.138+19%0.136+20%0.149+10%
Operating Margin----0%0.048-100%0.080-100%0.125-100%
Operating Ratio--1.3311.435-7%1.251+6%1.016+31%1.136+17%
Pb Ratio0.610-4%0.6320.654-3%0.723-13%0.879-28%1.192-47%
Pe Ratio4.941-4%5.1245.563-8%7.041-27%4.384+17%5.772-11%
Price Per Share26950.000-4%27950.00027912.500+0%27762.500+1%29670.000-6%32822.414-15%
Price To Free Cash Flow Ratio---10.232-100%8.149-100%7.962-100%10.367-100%
Price To Total Gains Ratio19.763-4%20.49731.636-35%20.628-1%35.261-42%33.795-39%
Quick Ratio---0.634-100%3.441-100%2.438-100%1.994-100%
Return On Assets--0.0260.025+4%0.024+11%0.023+15%0.026+1%
Return On Equity--0.0310.030+3%0.029+6%0.030+2%0.038-18%
Total Gains Per Share--1363.6441003.303+36%1472.715-7%1192.237+14%1765.321-23%
Usd Book Value--181894155.800175658246.104+4%159682813.903+14%145308683.013+25%128019052.010+42%
Usd Book Value Change Per Share--0.9550.702+36%0.796+20%0.658+45%1.067-11%
Usd Book Value Per Share--30.93429.874+4%26.891+15%24.393+27%21.457+44%
Usd Dividend Per Share----0%0.235-100%0.177-100%0.169-100%
Usd Enterprise Value--83021374.80082530897.999+1%150329716.369-45%125352278.424-34%120691174.691-31%
Usd Eps--0.9550.894+7%0.782+22%0.730+31%0.751+27%
Usd Free Cash Flow---1853899.612-100%4052779.033-100%4520192.673-100%3317180.893-100%
Usd Market Cap110926200.000-4%115042200.000114887850.000+0%115454850.0000%123915540.000-7%137372441.379-16%
Usd Price Per Share18.865-4%19.56519.539+0%19.434+1%20.769-6%22.976-15%
Usd Profit--5612757.5005256300.581+7%4641117.261+21%4346635.734+29%4486178.067+25%
Usd Revenue--34218349.20034659089.176-1%33645356.213+2%31602994.910+8%30238361.741+13%
Usd Total Gains Per Share--0.9550.702+36%1.031-7%0.835+14%1.236-23%
 EOD+3 -4MRQTTM+25 -6YOY+18 -165Y+19 -1510Y+16 -18

3.3 Fundamental Score

Let's check the fundamental score of Daihan Pharmaceutical Co.Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-154.941
Price to Book Ratio (EOD)Between0-10.610
Net Profit Margin (MRQ)Greater than00.164
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.000
Current Ratio (MRQ)Greater than13.235
Debt to Asset Ratio (MRQ)Less than10.150
Debt to Equity Ratio (MRQ)Less than10.176
Return on Equity (MRQ)Greater than0.150.031
Return on Assets (MRQ)Greater than0.050.026
Total6/10 (60.0%)

3.4 Technical Score

Let's check the technical score of Daihan Pharmaceutical Co.Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose26,800.000
Total0/1 (0.0%)

4. In-depth Analysis

4.1 About Daihan Pharmaceutical Co.Ltd

Daihan Pharmaceutical Co.,Ltd. engages in the manufacture and sale of therapeutic drugs in South Korea. The company offers various drugs, such as prescription, OTC, and quasi drugs, as well as offers various infusion related solutions. Daihan Pharmaceutical Co.,Ltd. was founded in 1945 and is headquartered in Seoul, South Korea.

Fundamental data was last updated by Penke on 2024-12-09 11:38:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is cheap.
Based on how much money comes from the company's main activities, the company is cheap.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Daihan earns for each ₩1 of revenue.

  • Above 10% is considered healthy but always compare Daihan to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 16.4% means that ₩0.16 for each ₩1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Daihan Pharmaceutical Co.Ltd:

  • The MRQ is 16.4%. The company is making a huge profit. +2
  • The TTM is 15.2%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ16.4%TTM15.2%+1.2%
TTM15.2%YOY13.8%+1.4%
TTM15.2%5Y13.6%+1.5%
5Y13.6%10Y14.9%-1.2%
4.3.1.2. Return on Assets

Shows how efficient Daihan is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Daihan to the Drug Manufacturers - Specialty & Generic industry mean.
  • 2.6% Return on Assets means that Daihan generated ₩0.03 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Daihan Pharmaceutical Co.Ltd:

  • The MRQ is 2.6%. Using its assets, the company is less efficient in making profit.
  • The TTM is 2.5%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ2.6%TTM2.5%+0.1%
TTM2.5%YOY2.4%+0.2%
TTM2.5%5Y2.3%+0.2%
5Y2.3%10Y2.6%-0.3%
4.3.1.3. Return on Equity

Shows how efficient Daihan is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Daihan to the Drug Manufacturers - Specialty & Generic industry mean.
  • 3.1% Return on Equity means Daihan generated ₩0.03 for each ₩1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Daihan Pharmaceutical Co.Ltd:

  • The MRQ is 3.1%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 3.0%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ3.1%TTM3.0%+0.1%
TTM3.0%YOY2.9%+0.1%
TTM3.0%5Y3.0%0.0%
5Y3.0%10Y3.8%-0.7%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Daihan Pharmaceutical Co.Ltd.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Daihan is operating .

  • Measures how much profit Daihan makes for each ₩1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Daihan to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated ₩0.00  for each ₩1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Daihan Pharmaceutical Co.Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY4.8%-4.8%
TTM-5Y8.0%-8.0%
5Y8.0%10Y12.5%-4.4%
4.3.2.2. Operating Ratio

Measures how efficient Daihan is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.33 means that the operating costs are ₩1.33 for each ₩1 in net sales.

Let's take a look of the Operating Ratio trends of Daihan Pharmaceutical Co.Ltd:

  • The MRQ is 1.331. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.435. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.331TTM1.435-0.104
TTM1.435YOY1.251+0.185
TTM1.4355Y1.016+0.419
5Y1.01610Y1.136-0.120
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Daihan Pharmaceutical Co.Ltd.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Daihan is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 3.23 means the company has ₩3.23 in assets for each ₩1 in short-term debts.

Let's take a look of the Current Ratio trends of Daihan Pharmaceutical Co.Ltd:

  • The MRQ is 3.235. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.591. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.235TTM3.591-0.356
TTM3.591YOY3.880-0.289
TTM3.5915Y3.340+0.251
5Y3.34010Y2.900+0.440
4.4.3.2. Quick Ratio

Measures if Daihan is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Daihan to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.00 means the company can pay off ₩0.00 for each ₩1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Daihan Pharmaceutical Co.Ltd:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM0.634-0.634
TTM0.634YOY3.441-2.807
TTM0.6345Y2.438-1.804
5Y2.43810Y1.994+0.444
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Daihan Pharmaceutical Co.Ltd.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Daihan assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Daihan to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.15 means that Daihan assets are financed with 15.0% credit (debt) and the remaining percentage (100% - 15.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Daihan Pharmaceutical Co.Ltd:

  • The MRQ is 0.150. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.156. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.150TTM0.156-0.006
TTM0.156YOY0.183-0.027
TTM0.1565Y0.238-0.082
5Y0.23810Y0.284-0.046
4.5.4.2. Debt to Equity Ratio

Measures if Daihan is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Daihan to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 17.6% means that company has ₩0.18 debt for each ₩1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Daihan Pharmaceutical Co.Ltd:

  • The MRQ is 0.176. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.184. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.176TTM0.184-0.008
TTM0.184YOY0.225-0.041
TTM0.1845Y0.321-0.136
5Y0.32110Y0.418-0.098
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₩1 in earnings Daihan generates.

  • Above 15 is considered overpriced but always compare Daihan to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 5.12 means the investor is paying ₩5.12 for every ₩1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Daihan Pharmaceutical Co.Ltd:

  • The EOD is 4.941. Based on the earnings, the company is cheap. +2
  • The MRQ is 5.124. Based on the earnings, the company is cheap. +2
  • The TTM is 5.563. Based on the earnings, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD4.941MRQ5.124-0.183
MRQ5.124TTM5.563-0.438
TTM5.563YOY7.041-1.478
TTM5.5635Y4.384+1.179
5Y4.38410Y5.772-1.388
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Daihan Pharmaceutical Co.Ltd:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM10.232-10.232
TTM10.232YOY8.149+2.083
TTM10.2325Y7.962+2.270
5Y7.96210Y10.367-2.404
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Daihan is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 0.63 means the investor is paying ₩0.63 for each ₩1 in book value.

Let's take a look of the Price to Book Ratio trends of Daihan Pharmaceutical Co.Ltd:

  • The EOD is 0.610. Based on the equity, the company is cheap. +2
  • The MRQ is 0.632. Based on the equity, the company is cheap. +2
  • The TTM is 0.654. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.610MRQ0.632-0.023
MRQ0.632TTM0.654-0.022
TTM0.654YOY0.723-0.069
TTM0.6545Y0.879-0.224
5Y0.87910Y1.192-0.314
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in KRW. All numbers in thousands.

Summary
Total Assets305,592,830
Total Liabilities45,744,036
Total Stockholder Equity259,848,794
 As reported
Total Liabilities 45,744,036
Total Stockholder Equity+ 259,848,794
Total Assets = 305,592,830

Assets

Total Assets305,592,830
Total Current Assets126,961,816
Long-term Assets178,631,015
Total Current Assets
Total Current Assets  (as reported)126,961,816
Total Current Assets  (calculated)0
+/- 126,961,816
Long-term Assets
Long-term Assets  (as reported)178,631,015
Long-term Assets  (calculated)0
+/- 178,631,015

Liabilities & Shareholders' Equity

Total Current Liabilities39,252,341
Long-term Liabilities6,491,695
Total Stockholder Equity259,848,794
Total Current Liabilities
Total Current Liabilities  (as reported)39,252,341
Total Current Liabilities  (calculated)0
+/- 39,252,341
Long-term Liabilities
Long-term Liabilities  (as reported)6,491,695
Long-term Liabilities  (calculated)0
+/- 6,491,695
Total Stockholder Equity
Total Stockholder Equity (as reported)259,848,794
Total Stockholder Equity (calculated)0
+/- 259,848,794
Other
Common Stock Shares Outstanding 5,880
Net Working Capital 87,709,475



6.2. Balance Sheets Structured

Currency in KRW. All numbers in thousands.

 Trend2024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
> Total Assets 
164,805,683
170,550,620
184,403,448
201,581,404
233,285,257
228,931,193
234,754,644
231,909,671
233,878,581
239,467,991
246,851,673
252,453,398
254,109,652
256,370,231
253,089,722
256,709,170
263,355,211
265,313,451
272,542,222
274,035,384
278,819,960
285,158,210
276,979,912
276,725,214
278,008,299
287,085,179
294,252,469
301,727,797
305,592,830
305,592,830301,727,797294,252,469287,085,179278,008,299276,725,214276,979,912285,158,210278,819,960274,035,384272,542,222265,313,451263,355,211256,709,170253,089,722256,370,231254,109,652252,453,398246,851,673239,467,991233,878,581231,909,671234,754,644228,931,193233,285,257201,581,404184,403,448170,550,620164,805,683
   > Total Current Assets 
76,043,719
80,164,671
83,471,918
97,247,017
96,468,201
101,140,667
104,967,110
101,645,896
101,548,444
106,856,714
111,130,143
118,541,277
123,504,653
126,265,718
121,683,987
125,781,343
129,096,778
131,212,573
147,538,815
150,154,263
159,332,450
164,546,400
155,885,924
155,740,190
154,539,215
160,262,971
159,904,570
129,777,852
126,961,816
126,961,816129,777,852159,904,570160,262,971154,539,215155,740,190155,885,924164,546,400159,332,450150,154,263147,538,815131,212,573129,096,778125,781,343121,683,987126,265,718123,504,653118,541,277111,130,143106,856,714101,548,444101,645,896104,967,110101,140,66796,468,20197,247,01783,471,91880,164,67176,043,719
       Cash And Cash Equivalents 
7,248,116
7,602,937
13,091,275
28,916,864
26,843,659
33,018,631
40,505,810
37,476,059
37,147,699
43,613,616
44,737,814
55,071,542
59,992,195
59,675,978
61,300,988
67,127,866
71,676,737
75,712,110
39,014
236,757
231,175
174,522
265,512
338,490
261,799
99,631,143
101,501,357
69,341,669
0
069,341,669101,501,35799,631,143261,799338,490265,512174,522231,175236,75739,01475,712,11071,676,73767,127,86661,300,98859,675,97859,992,19555,071,54244,737,81443,613,61637,147,69937,476,05940,505,81033,018,63126,843,65928,916,86413,091,2757,602,9377,248,116
       Short-term Investments 
2,447,120
2,345,000
3,026,849
2,704,536
2,612,490
2,760,444
2,120,000
3,220,000
3,670,000
3,880,000
9,030,495
0
0
11,406,329
6,201,810
5,736,292
2,780,000
3,310,000
12,650,000
12,580,000
16,510,000
16,040,000
6,750,000
5,842,864
2,905,850
3,446,143
2,858,098
3,897,730
0
03,897,7302,858,0983,446,1432,905,8505,842,8646,750,00016,040,00016,510,00012,580,00012,650,0003,310,0002,780,0005,736,2926,201,81011,406,329009,030,4953,880,0003,670,0003,220,0002,120,0002,760,4442,612,4902,704,5363,026,8492,345,0002,447,120
       Net Receivables 
50,050,285
52,942,950
50,354,774
46,941,701
46,757,068
44,198,346
40,206,243
38,449,048
39,433,066
37,833,871
36,160,005
32,646,178
30,037,570
31,325,254
29,077,281
29,174,361
31,304,493
29,624,053
30,313,788
29,067,683
30,452,754
31,030,601
32,332,040
29,909,825
31,621,558
33,075,852
30,856,949
28,521,138
0
028,521,13830,856,94933,075,85231,621,55829,909,82532,332,04031,030,60130,452,75429,067,68330,313,78829,624,05331,304,49329,174,36129,077,28131,325,25430,037,57032,646,17836,160,00537,833,87139,433,06638,449,04840,206,24344,198,34646,757,06846,941,70150,354,77452,942,95050,050,285
       Inventory 
16,210,604
17,187,594
16,913,253
16,763,151
18,755,591
19,899,241
20,837,076
21,116,247
20,022,837
20,170,499
19,950,839
19,312,838
20,990,541
21,878,743
23,733,276
22,311,709
21,721,162
21,089,664
20,632,025
22,150,599
24,921,768
23,950,334
24,939,416
25,160,721
25,002,571
23,017,231
23,587,668
26,680,373
0
026,680,37323,587,66823,017,23125,002,57125,160,72124,939,41623,950,33424,921,76822,150,59920,632,02521,089,66421,721,16222,311,70923,733,27621,878,74320,990,54119,312,83819,950,83920,170,49920,022,83721,116,24720,837,07619,899,24118,755,59116,763,15116,913,25317,187,59416,210,604
       Other Current Assets 
35,000
51,190
35,000
1,876,977
1,470,745
1,240,098
1,252,685
1,282,534
1,179,390
100,000
1,054,928
959,283
1,141,781
1,127,592
1,111,107
1,010,462
1,211,017
1,219,319
0
0
0
1,615,144
1,026,354
981,618
986,901
957,893
935,433
978,386
0
0978,386935,433957,893986,901981,6181,026,3541,615,1440001,219,3191,211,0171,010,4621,111,1071,127,5921,141,781959,2831,054,928100,0001,179,3901,282,5341,252,6851,240,0981,470,7451,876,97735,00051,19035,000
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
121,093,989
120,985,023
123,469,085
126,822,207
134,347,899
171,949,945
178,631,015
178,631,015171,949,945134,347,899126,822,207123,469,085120,985,023121,093,9890000000000000000000000
       Property Plant Equipment 
82,088,860
82,798,349
93,794,708
96,331,854
116,542,192
118,351,696
120,237,759
120,580,497
121,896,393
121,239,482
125,820,189
124,655,409
122,741,820
121,618,222
113,396,465
112,993,171
113,476,897
113,314,421
113,831,479
113,080,068
111,547,984
112,243,700
113,235,617
112,431,866
115,148,371
118,656,726
125,852,650
128,608,282
0
0128,608,282125,852,650118,656,726115,148,371112,431,866113,235,617112,243,700111,547,984113,080,068113,831,479113,314,421113,476,897112,993,171113,396,465121,618,222122,741,820124,655,409125,820,189121,239,482121,896,393120,580,497120,237,759118,351,696116,542,19296,331,85493,794,70882,798,34982,088,860
       Long Term Investments 
5,726,684
6,561,926
5,742,476
6,581,959
6,611,461
7,690,963
7,812,622
7,919,986
7,499,515
8,520,243
8,436,891
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000008,436,8918,520,2437,499,5157,919,9867,812,6227,690,9636,611,4616,581,9595,742,4766,561,9265,726,684
       Intangible Assets 
410,976
409,854
408,752
407,657
406,563
405,493
404,283
403,224
402,179
401,257
400,399
399,554
398,747
398,012
397,508
397,291
397,102
397,013
397,013
397,013
397,013
397,013
397,013
397,013
397,013
397,013
397,013
397,013
0
0397,013397,013397,013397,013397,013397,013397,013397,013397,013397,013397,013397,102397,291397,508398,012398,747399,554400,399401,257402,179403,224404,283405,493406,563407,657408,752409,854410,976
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000
> Total Liabilities 
61,199,038
59,238,371
68,522,855
80,800,824
105,470,344
94,227,943
94,392,961
86,785,719
81,492,663
80,404,635
80,076,416
80,855,782
77,514,126
73,289,914
71,166,277
71,775,833
72,826,439
67,786,231
69,734,206
67,197,951
65,048,230
63,219,549
51,581,827
47,839,840
41,757,196
42,977,223
46,278,381
49,897,228
45,744,036
45,744,03649,897,22846,278,38142,977,22341,757,19647,839,84051,581,82763,219,54965,048,23067,197,95169,734,20667,786,23172,826,43971,775,83371,166,27773,289,91477,514,12680,855,78280,076,41680,404,63581,492,66386,785,71994,392,96194,227,943105,470,34480,800,82468,522,85559,238,37161,199,038
   > Total Current Liabilities 
42,748,788
41,602,223
43,422,101
53,138,288
54,500,847
54,816,082
55,495,625
49,235,637
44,807,990
44,256,675
42,716,531
44,138,637
41,840,447
38,784,623
39,224,432
40,272,179
42,388,742
38,481,052
46,118,721
43,914,813
42,953,054
42,213,682
42,685,523
42,090,262
36,193,135
37,590,512
41,300,252
43,363,140
39,252,341
39,252,34143,363,14041,300,25237,590,51236,193,13542,090,26242,685,52342,213,68242,953,05443,914,81346,118,72138,481,05242,388,74240,272,17939,224,43238,784,62341,840,44744,138,63742,716,53144,256,67544,807,99049,235,63755,495,62554,816,08254,500,84753,138,28843,422,10141,602,22342,748,788
       Short-term Debt 
14,200,000
3,100,000
3,200,000
3,000,000
2,800,000
2,600,000
2,400,000
2,300,000
2,200,000
5,000,000
5,000,000
5,000,000
3,700,000
3,700,000
3,700,000
3,700,000
2,700,000
2,700,000
2,700,000
2,700,000
2,500,000
2,500,000
2,500,000
2,500,000
0
0
0
0
0
000002,500,0002,500,0002,500,0002,500,0002,700,0002,700,0002,700,0002,700,0003,700,0003,700,0003,700,0003,700,0005,000,0005,000,0005,000,0002,200,0002,300,0002,400,0002,600,0002,800,0003,000,0003,200,0003,100,00014,200,000
       Short Long Term Debt 
14,200,000
3,100,000
3,200,000
3,000,000
2,800,000
2,600,000
2,400,000
2,300,000
2,200,000
2,100,000
2,043,665
0
0
0
0
0
0
0
0
0
0
9,300,000
2,500,000
2,500,000
0
0
0
0
0
000002,500,0002,500,0009,300,00000000000002,043,6652,100,0002,200,0002,300,0002,400,0002,600,0002,800,0003,000,0003,200,0003,100,00014,200,000
       Accounts payable 
19,633,457
20,478,057
17,770,902
16,930,544
20,340,917
21,568,526
20,174,174
19,766,521
19,347,139
18,948,460
15,953,027
17,224,062
18,650,813
15,879,379
15,497,362
16,051,172
17,827,335
14,883,161
0
0
0
16,536,941
18,104,219
16,276,050
17,023,082
18,732,290
17,226,608
18,236,397
0
018,236,39717,226,60818,732,29017,023,08216,276,05018,104,21916,536,94100014,883,16117,827,33516,051,17215,497,36215,879,37918,650,81317,224,06215,953,02718,948,46019,347,13919,766,52120,174,17421,568,52620,340,91716,930,54417,770,90220,478,05719,633,457
       Other Current Liabilities 
14,826,706
12,674,267
17,110,607
20,839,365
18,913,614
18,173,744
20,473,847
21,562,091
17,640,251
17,656,340
19,072,866
18,839,418
15,913,678
14,909,801
15,145,321
15,884,281
17,265,368
16,352,932
0
0
0
15,833,275
2,294,254
2,356,214
2,370,761
2,400,972
2,378,792
0
0
002,378,7922,400,9722,370,7612,356,2142,294,25415,833,27500016,352,93217,265,36815,884,28115,145,32114,909,80115,913,67818,839,41819,072,86617,656,34017,640,25121,562,09120,473,84718,173,74418,913,61420,839,36517,110,60712,674,26714,826,706
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8,896,304
5,749,579
5,564,061
5,386,711
4,978,129
6,534,088
6,491,695
6,491,6956,534,0884,978,1295,386,7115,564,0615,749,5798,896,3040000000000000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
22,500,000
24,800,000
23,842,563
22,865,890
21,826,130
20,816,572
19,806,675
18,804,490
17,800,799
14,000,000
13,000,000
12,000,000
11,000,000
4,000,000
0
0
0
0
0
0
0000004,000,00011,000,00012,000,00013,000,00014,000,00017,800,79918,804,49019,806,67520,816,57221,826,13022,865,89023,842,56324,800,00022,500,000000000000
       Capital Lease Obligations 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
799
0
0
0
0
0
0
0
0000000799000000000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
1
0
0
00101000000000000000000000000
> Total Stockholder Equity
103,606,645
111,312,248
115,880,593
120,780,580
127,814,913
134,703,250
140,361,683
145,123,952
152,385,918
159,063,356
166,775,257
171,597,617
176,595,525
183,080,318
181,923,445
184,933,338
190,528,773
197,527,220
202,808,017
206,837,434
213,771,731
221,938,661
225,398,085
228,885,373
236,251,103
244,107,955
247,974,088
251,830,569
259,848,794
259,848,794251,830,569247,974,088244,107,955236,251,103228,885,373225,398,085221,938,661213,771,731206,837,434202,808,017197,527,220190,528,773184,933,338181,923,445183,080,318176,595,525171,597,617166,775,257159,063,356152,385,918145,123,952140,361,683134,703,250127,814,913120,780,580115,880,593111,312,248103,606,645
   Common Stock
3,000,000
3,000,000
3,000,000
3,000,000
3,000,000
3,000,000
3,000,000
3,000,000
3,000,000
3,000,000
3,000,000
3,000,000
3,000,000
3,000,000
3,000,000
3,000,000
3,000,000
3,000,000
3,000,000
3,000,000
3,000,000
3,000,000
3,000,000
3,000,000
3,000,000
0
0
0
0
00003,000,0003,000,0003,000,0003,000,0003,000,0003,000,0003,000,0003,000,0003,000,0003,000,0003,000,0003,000,0003,000,0003,000,0003,000,0003,000,0003,000,0003,000,0003,000,0003,000,0003,000,0003,000,0003,000,0003,000,0003,000,000
   Retained Earnings 
90,876,735
98,582,338
103,150,682
108,050,669
115,085,003
121,973,339
127,631,773
132,394,041
139,656,007
155,887,433
154,045,346
158,867,706
163,865,615
170,350,407
169,193,534
172,203,427
177,798,862
184,797,310
199,632,094
203,661,511
210,595,808
209,208,750
225,640,205
229,127,493
236,493,223
244,350,075
248,216,208
252,072,689
0
0252,072,689248,216,208244,350,075236,493,223229,127,493225,640,205209,208,750210,595,808203,661,511199,632,094184,797,310177,798,862172,203,427169,193,534170,350,407163,865,615158,867,706154,045,346155,887,433139,656,007132,394,041127,631,773121,973,339115,085,003108,050,669103,150,68298,582,33890,876,735
   Capital Surplus 00000000000000000000000000000
   Treasury Stock00000000000000000000000000000
   Other Stockholders Equity 
9,553,987
9,553,987
9,553,988
9,553,988
9,553,987
9,553,988
9,553,988
9,553,988
9,553,988
175,923
9,553,988
9,553,988
9,553,988
9,553,988
9,553,988
9,553,988
9,553,988
9,553,988
175,923
175,923
175,923
9,553,988
-3,242,120
-3,242,120
-3,242,120
0
0
0
0
0000-3,242,120-3,242,120-3,242,1209,553,988175,923175,923175,9239,553,9889,553,9889,553,9889,553,9889,553,9889,553,9889,553,9889,553,988175,9239,553,9889,553,9889,553,9889,553,9889,553,9879,553,9889,553,9889,553,9879,553,987



6.3. Balance Sheets

Currency in KRW. All numbers in thousands.




6.4. Cash Flows

Currency in KRW. All numbers in thousands.




6.5. Income Statements

Currency in KRW. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in KRW. All numbers in thousands.

Gross Profit (+$)
totalRevenue195,911,459
Cost of Revenue-129,989,171
Gross Profit65,922,28865,922,288
 
Operating Income (+$)
Gross Profit65,922,288
Operating Expense-160,116,087
Operating Income35,795,372-94,193,799
 
Operating Expense (+$)
Research Development1,641,152
Selling General Administrative12,489,195
Selling And Marketing Expenses0
Operating Expense160,116,08714,130,347
 
Net Interest Income (+$)
Interest Income87,180
Interest Expense-52,468
Other Finance Cost-0
Net Interest Income34,712
 
Pretax Income (+$)
Operating Income35,795,372
Net Interest Income34,712
Other Non-Operating Income Expenses0
Income Before Tax (EBT)36,733,57835,795,372
EBIT - interestExpense = -52,468
28,426,315
28,478,783
Interest Expense52,468
Earnings Before Interest and Taxes (EBIT)036,786,047
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax36,733,578
Tax Provision-8,307,263
Net Income From Continuing Ops28,426,31528,426,315
Net Income28,426,315
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net0-34,712
 

Technical Analysis of Daihan
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Daihan. The general trend of Daihan is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Daihan's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Daihan Pharmaceutical Co.Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 27,450 < 27,500 < 27,550.

The bearish price targets are: 25,450 > 25,050 > 23,750.

Tweet this
Daihan Pharmaceutical Co.Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Daihan Pharmaceutical Co.Ltd. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Daihan Pharmaceutical Co.Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Daihan Pharmaceutical Co.Ltd.

Daihan Pharmaceutical Co.Ltd Daily Moving Average Convergence/Divergence (MACD) ChartDaihan Pharmaceutical Co.Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Daihan Pharmaceutical Co.Ltd. The current adx is .

Daihan Pharmaceutical Co.Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Daihan Pharmaceutical Co.Ltd.

Daihan Pharmaceutical Co.Ltd Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Daihan Pharmaceutical Co.Ltd.

Daihan Pharmaceutical Co.Ltd Daily Relative Strength Index (RSI) ChartDaihan Pharmaceutical Co.Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Daihan Pharmaceutical Co.Ltd.

Daihan Pharmaceutical Co.Ltd Daily Stochastic Oscillator ChartDaihan Pharmaceutical Co.Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Daihan Pharmaceutical Co.Ltd.

Daihan Pharmaceutical Co.Ltd Daily Commodity Channel Index (CCI) ChartDaihan Pharmaceutical Co.Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Daihan Pharmaceutical Co.Ltd.

Daihan Pharmaceutical Co.Ltd Daily Chande Momentum Oscillator (CMO) ChartDaihan Pharmaceutical Co.Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Daihan Pharmaceutical Co.Ltd.

Daihan Pharmaceutical Co.Ltd Daily Williams %R ChartDaihan Pharmaceutical Co.Ltd Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Daihan Pharmaceutical Co.Ltd.

Daihan Pharmaceutical Co.Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Daihan Pharmaceutical Co.Ltd.

Daihan Pharmaceutical Co.Ltd Daily Average True Range (ATR) ChartDaihan Pharmaceutical Co.Ltd Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Daihan Pharmaceutical Co.Ltd.

Daihan Pharmaceutical Co.Ltd Daily On-Balance Volume (OBV) ChartDaihan Pharmaceutical Co.Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Daihan Pharmaceutical Co.Ltd.

Daihan Pharmaceutical Co.Ltd Daily Money Flow Index (MFI) ChartDaihan Pharmaceutical Co.Ltd Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Daihan Pharmaceutical Co.Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-07-24SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-07-25WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-07-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-29CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-07-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-01CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-08-05STOCH SHORT EXITThe %K line crosses above the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-06RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-07MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-08-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-12MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-08-16SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-08-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-21CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-22STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-08-27SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-08-30CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-09-02STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-09-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-09RSI LONG ENTRY SHORT CLOSE30 crossover to upside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-09-10DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-09-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-09-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-09-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-09-24WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-09-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-07STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-10CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-10-15STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-10-16BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-10-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-18STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-10-21STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-10-24WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-10-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-29RSI LONG ENTRY SHORT CLOSE30 crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-10-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-31WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-04RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-11-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-11-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-13ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-11-18CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-11-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-28STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-02STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-12-03RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-12-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-12-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-12-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-12-10STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-12STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-12-16DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.

6.3. Candlestick Patterns

Daihan Pharmaceutical Co.Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Daihan Pharmaceutical Co.Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose26,800.000
Total0/1 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Daihan with someone you think should read this too:
  • Are you bullish or bearish on Daihan? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Daihan? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Daihan Pharmaceutical Co.Ltd

I send you an email if I find something interesting about Daihan Pharmaceutical Co.Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Daihan Pharmaceutical Co.Ltd.

Receive notifications about Daihan Pharmaceutical Co.Ltd in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.